In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
- 14 July 1990
- journal article
- Published by Elsevier in The Lancet
- Vol. 336 (8707) , 71-75
- https://doi.org/10.1016/0140-6736(90)91590-7
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trialJournal of the American College of Cardiology, 1990
- GISSI-2: mortality plus extensive left-ventricular damage as "end-point"The Lancet, 1990
- Comparison of High-Dose with Low-Dose Subcutaneous Heparin to Prevent Left Ventricular Mural Thrombosis in Patients with Acute Transmural Anterior Myocardial InfarctionNew England Journal of Medicine, 1989
- A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction.Circulation, 1989
- TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1988
- Adjusted Subcutaneous Heparin or Continuous Intravenous Heparin in Patients with Acute Deep Vein ThrombosisAnnals of Internal Medicine, 1987
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.Circulation, 1987
- RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTIONThe Lancet, 1985
- An objective study of alternative methods of heparin administrationThrombosis Research, 1980